progressive familial heart block type II

Summary

progressive familial heart block type II (MONDO:0007701) is a disease. A subtype of progressive familial heart block — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	progressive familial heart block type II
Mondo ID	MONDO:0007701
MeSH	C564202
OMIM	140400
DOID	DOID:0111075
SNOMED CT	698251009
UMLS	C1841658
MedGen	333884
GARD	0004879
Is cancer (heuristic)	no

Also known as: heart block progressive familial type 2 · PFHB2 · PFHBII · progressive familial heart block type 2 · progressive familial heart block, type II

Disease family

This is a subtype of progressive familial heart block. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › heart conduction disease › progressive familial heart block › progressive familial heart block type II

Related subtypes (2): progressive familial heart block, type 1A, progressive familial heart block type IB

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.